GenSight Biologics S.A. (EPA:SIGHT)
France · Delayed Price · Currency is EUR 0.0836
+0.0020 (2.45%)
Aug 3, 2026, 12:37 PM CET
GenSight Biologics Stock Forecast
Stock Price Forecast
According to 3 analysts polled by S&P Global, GenSight Biologics stock has a consensus rating of "Buy" and an average price target of €0.31. The average 1-year stock price forecast is 270.81% higher than the current stock price, while the lowest is €0.21 (+151.20%) and the highest is €0.40 (+378.47%).
Price Target: €0.31 (+270.81%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for GenSight Biologics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Jan '26 | Mar '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Hold Maintains €0.08 | Hold | Maintains | €0.08 | -4.31% | Jul 16, 2026 |
| Kepler Capital | Kepler Capital | Hold Maintains €0.40 | Hold | Maintains | €0.40 | +378.47% | Apr 8, 2026 |
Financial Forecast
Revenue This Year
11.20M
from 652.00K
Increased by 1,617.79%
Revenue Next Year
41.60M
from 11.20M
Increased by 271.43%
EPS This Year
-0.22
from -0.08
EPS Next Year
-0.81
from -0.22
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is EUR.